A phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor.

被引：0

作者：

Hao, Desiree

Chu, Quincy

Welch, Stephen

Yau, Cindy Y. F.

Spratlin, Jennifer L.

Tang, Patricia

MacKenzie, Mary J.

Townsley, Carol A.

Arndt, Diane

Johnson, Laureen

Trapsa, Daniela

Degendorfer, Pamela

Kulkarni, Sujay

Jawlekar, Gajendra

Dhobe, Poornima

Oza, Amit M.

机构：

[1] Tom Baker Canc Clin, Calgary, AB, Canada

[2] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada

[3] London Reg Canc Program, London, ON, Canada

[4] Ozmosis Res Inc, Toronto, ON, Canada

[5] Piramal Healthcare Ltd, Bombay, Maharashtra, India

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3013

引用

页数：1